Smoking Weed

Smoking Weed Improves Brain Functions According to Harvard Study

Posted Leave a commentPosted in Medical Marijuana

Smoking Weed Improves Brain Functions According to Harvard Study. Scientific findings recently published in Frontiers in Pharmacology may have cleared up that mystery of smoking weed and brain function once and for all. Preliminary investigations by medical researchers from McLean Hospital, Harvard Medical School, and Tufts University indicate that pot use improves cognitive performance.

Cognitive performance, no need to tell you, is “our ability to utilize the knowledge acquired by mental processes in our brains.” In other words, perform tasks that require thinking, as in to be so goddamn smart.

The behavioral scientists behind the work summarized in “Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana (Smoking weed) on Executive Function” tracked 24 certified medical-marijuana patients over a three-month dosing period. The patients were repeatedly measured for cognitive proficiency through challenges to the intelligence that included the Stroop Color Word Test and Trail Making Test after smoking weed.

Staci Gruber, PhD, director of the Marijuana Investigations for Neuroscientific Discovery (MIND) program at McLean Hospital—Harvard Medical School’s largest psychiatric affiliate—is the lead “Splendor in the Grass?” researcher. Her initial report is twofold positive. For one thing, weed treatment led to patients breezing through an array of brainteasers with enhanced speed and accuracy.

From a McLean Hospital report:

“After three months of medical marijuana treatment, patients actually performed better, in terms of their ability to perform certain cognitive tasks, specifically those mediated by the frontal cortex,” explained Gruber.

Study participants also reported improvements in their specific clinical conditions, sleep, and overall health as well as a decreased use of conventional medications, particularly opiates.

“We saw a 42 percent reduction in opioid use,” reported Gruber. “This is significant, particularly for those of us in Massachusetts and other areas of the country where the opioid epidemic is ravaging so many. This preliminary finding certainly warrants deeper and broader investigation.”

In less than a week, electorates in five states (one of them being Massachusetts) have the opportunity to vote themselves into the legal-marijuana club. If just one of these states, California for instance, opts for legal adult use, literally millions more Americans will be granted the option to use marijuana without fear of police intervention. Perhaps not everyone who picks up a joint in this newly normalized landscape will become as intelligent as the Kindland smarties.

But you don’t need to be a brilliant visionary to recognize that the preliminary findings from McLean Hospital’s pilot study assessing the favorable impacts of cannabis on adult human brains demand further exploration. Deeper, broader investigations into marijuana’s ability to improve our mental functioning and reduce our susceptibility to opioid dependence should be happening sooner than later.

In that regard, “Splendor in the Grass?” lead Staci Gruber appears to be every bit as invested in the public wellbeing as she is smart in her approach to unraveling and establishing best marijuana practices.

“People are going to use it,” she concludes. “It’s up to us to figure out the very best and safest ways in which they can do that.”

Original Article written by ALLAN MACDONELL, reposted from Kindland

Cannabis classesThe Women’s Cannabis Chamber of Commerce is dedicated to the advancement of women within the Cannabis Industry and canna-centric businesses. WCCC moves beyond empowerment. WCCC offers courses created to provide women with the tools and knowledge to open businesses. WCCC provides mentorship through a community of entrepreneurs dedicated to supporting other women and adhering to a standard of honesty and integrity.  Women’s Cannabis Chamber of Commerce

Emerald Cup

Emerald Cup Victory result of helping Grandma’s pain

Posted Leave a commentPosted in Medical Marijuana

Emerald Cup Victory: In a little over a year, Chelsea Dudgeon has gone from whipping up experimental topicals for her grandma to an Emerald Cup winner ready to take her company to the next level.

The first batch of Deep Skin topical was made around March 2016, and forms the backbone of the quickly growing Newell’s Botanicals line.

“I just explicitly made it for my grandma,” Dudgeon said.

At the time she had no regards for the cost of production and used herbs from her garden she had on hand.

“I just knew I wanted to formulate something that was going to work because there was a lot of skepticism directed at me by my family,” Dudgeon said. “I’ve spent that last several years trying to convince them [cannabis] is a medicinal plant.”

Dudgeon ’s grandmother was in her 70s dealing with the results of a life of hard work. She’d spent the last 40 years working on her hands and knees scrubbing as a cleaning lady, this had led to a lot of joint deterioration, a new hip and arthritis. She has recently retired.

We asked Dudgeon, just a regular young woman from Sonoma far from the face of the green rush these days, if part of the process in developing her product line was due to a lack of satisfaction with what was already on the market.

“A lot of stuff smelled like weed,” she said. “That was a nonstarter.”

Her past exposure to the topical industry also had a certain lack of consistency.

“I wanted what I gave her to be both personal and effective,” she said.

The first batch she made lasted months. Dudgeon provided it to her grandmother in mason jars, then came batch two. She noted the first batch was a quart of this, a quart of that, and batch two was a lot more refined.

“We ended up going with the roll on so people won’t get greasy.”

The second batch was prepared about a month before the cup and she was torn over whether she would enter her experiment alongside some flowers she thought might have a chance at the Sustainability Award.

“In the aftermath of winning it was pretty funny,” said Dudgeon. “The reason I wanted to put a second product in was because I wanted two VIP competitor passes. I made this thing for grandma, [I thought] we can put it in a nice little bottle and make it all official.”

She wasn’t expecting to win but entering, “seemed like a good idea at the time.”

It was the first cup she had entered and the first time she had attended the Emerald Cup. the definitive outdoor cannabis world championship. Even placing in the prestigious contest that spans flowers, hash, edibles and topicals, is a huge notch in the belt of any grower, processor, or brand.

“I had no idea I was going to be competing against big name companies,” she said while noting the organic farming aspects were what got her most excited about the event she was essentially clueless on.

To this day she tells the tale without expectation, as if she didn’t take home one of the most competitive awards in America’s fastest growing industry, saying she wasn’t taking herself very seriously.

At the awards ceremony when they called her name she couldn’t believe it. She thought she’d heard the announcer say third but someone said, “No that was the last one… You won.” She made her way to the stage confused as she told security she believed she just won. She was right, grandma’s topical now called Deep Skin was the Emerald Cup champion.

“I wasn’t even sure we’d won until I was standing on the stage,” said she said. ”I didn’t know what to say.”

We asked Dudgeon about scaling up as she, in that moment, became extremely well positioned in the cannabis world with an Emerald Cup-winning topical she controlled 100 percent stake in.

“I didn’t sleep for two days,” she said. “I couldn’t stop shaking with excitement and terror.”

Now, six months later, she’s finally getting caught up. The excitement around the cup win and various write ups have had her working overtime. With the exception of a small loan from her father and her partner providing production assistance, she’s continued to build the brand solo. She now, like many, stand on the edge of California’s forthcoming regulated adult market ready to be a big winner… just with a better trophy case to back the effort than most.

Written By  on June 29, 2017 Reposted from CannabisNow.

 

DEA Approves Synthetic Cannabis Medication by Anti-Cannabis Pharmaceutical Giant

Posted Leave a commentPosted in Medical Marijuana

CannabisThe Drug Enforcement Administration has approved Syndros, a cannabis-based medication developed by pharmaceutical company Insys Therapeutics, for Schedule II status under the Controlled Substances Act, according to a Chicago Tribune report.

Syndros is an oral remedy that uses THC to treat nausea and vomiting, two of the most common symptoms caused by chemotherapy. The drug was pre-approved by the FDA last summer as a treatment for nausea, vomiting, and weightloss in cancer and AIDS patients.

If that name Insys sounds familiar, it’s probably because this is the pharma group that donated $500,000 last September to help defeat Arizona’s cannabis legalization campaign; and now the company has received DEA approval for its own cannabis-based drug. During the campaign, the company said it opposed the legalization measure because, “it [would fail] to protect the safety of Arizona’s citizens, and particularly its children.” Now, non-medical cannabis users in Arizona must still face felony charges for possessing even small amounts of the plant.

However, if safety were truly Insys’ biggest concern, they might rethink their aggressive marketing strategies for Subsys — a medication containing fentanyl, a dangerously powerful and addictive opiate that can be 50-100 times more powerful than Morphine.

“It appears they are trying to kill a non-pharmaceutical market for marijuana in order to line their own pockets,” a spokesperson for Arizona’s legalization campaign said last year.

It’s clear that in a world where anyone and everyone would be allowed to cultivate their own medicine, giant pharma companies such as Insys would inevitably lose revenue. However, according to Kevin Gallagher of Craft Concentrates and the Cannabis Business Alliance, Big Pharma interests may ultimately be surprised by the zeal and persistence of cannabis patients and advocates.

“This is a completely unique substance that is so readily available, and it’s so easy to take advantage of its healing nature, … it’ll be very interesting to see how that plays out,” Gallagher said in an interview with Westword.

“These pharmaceutical companies still think they’re going to win the battle in creating essentially fake cannabis and having to even compete with the real cannabis industry, but they’re not looking at the effects of certain terpenes or certain cannabinoids,” Gallagher said.

More and more Americans succumb to prescription opiate overdoses each year, while there remain zero recorded deaths contributed to the over-consumption of cannabis.

Original article from Ganjapreneur  March 27, 2017 written by Graham Abbott